0001209191-17-046159.txt : 20170725
0001209191-17-046159.hdr.sgml : 20170725
20170725162028
ACCESSION NUMBER: 0001209191-17-046159
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170719
FILED AS OF DATE: 20170725
DATE AS OF CHANGE: 20170725
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON SABRINA MARTUCCI
CENTRAL INDEX KEY: 0001199102
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36395
FILM NUMBER: 17980624
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dare Bioscience, Inc.
CENTRAL INDEX KEY: 0001401914
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 204139823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-769-9145
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: Cerulean Pharma Inc.
DATE OF NAME CHANGE: 20090714
FORMER COMPANY:
FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc
DATE OF NAME CHANGE: 20070604
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-07-19
0
0001401914
Dare Bioscience, Inc.
DARE
0001199102
JOHNSON SABRINA MARTUCCI
C/O DARE BIOSCIENCE, INC.
11119 NORTH TORREY PINES ROAD, SUITE 200
LA JOLLA
CA
92037
1
1
1
0
Chief Executive Officer
Common Stock
2017-07-19
4
A
0
962062
A
962062
I
By The Vincent S. Johnson and Sabrina M. Johnson Family Trust Dated February 4, 2005
In exchange for the issuance of shares of common stock and options to purchase shares of common stock of Dare Bioscience, Inc. (the "Corporation"), the Corporation acquired all of the issued and outstanding shares of common stock of Dare Bioscience Operations, Inc. ("Dare Operations") pursuant to the terms of a Stock Purchase Agreement, dated March 19, 2017, by and between the Corporation, Dare Operations and certain equityholders of Dare Operations party thereto, as filed with the Securities and Exchange Commission on Form 8-K on March 20, 2017 (such exchanges and issuances, the "Transaction").
The shares of common stock of the Corporation reported reflect the 10 for 1 reverse stock split effected by the Corporation on July 20, 2017. These shares of common stock of the Corporation were received in connection with the Transaction in exchange for 4,739,295 shares of Dare Operations common stock. On the effective date of the Transaction, the closing price of the common stock of the Corporation, as reported on The Nasdaq Capital Market, was $6.56 per share (on a post-split basis). Each share of common stock of Dare Operations was cancelled and exchanged for the right to receive 0.2029969047 shares of common stock of the Corporation (on a post-split basis).
/s/ Sebastian E. Lucier, Attorney-in-fact
2017-07-25